Understanding the Continuum of Care in SMA: The Importance of Early Diagnosis, Optimal Treatment, and Transitioning from Pediatric to Adult Care Teams

Released On
December 11, 2020

Expires On
December 11, 2021

Media Type
Internet

Completion Time
75 minutes

Specialty
Neurology, Obstetrics & Gynecology, Pediatrics

Topic(s)
Pediatrics

Scroll to the Bottom of this Information to Begin this Course

This activity is provided by Physicians’ Education Resource®, LLC.

This activity is supported by an educational grant from Biogen.

Credit Available

  • Physicians — maximum of 1.25 AMA PRA Category 1 Credit(s)
  • Nurses — 1.25 Contact Hours

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This activity is intended for OB/GYNs and neurologists, as well as physician assistants, nurse practitioners, and nurses involved in the diagnosis and management of SMA. This activity will provide education to a multidisciplinary team whom will be invited to participate.

Program Overview

This enduring continuing medical education (CME) activity is an archive of the live broadcast from November 17, 2020, featuring 4 spinal muscular atrophy (SMA) specialists who address the latest in evidence-based management strategies for this neurologic disorder. They provide their clinical data perspectives supporting the importance of early diagnosis, current and emerging treatments, and transitioning care from pediatric to adult medical specialties. Prenatal and newborn screening, implementing early treatments, safety and availability of new and emerging treatments, and overcoming barriers when transitioning care as patients with SMA age is also addressed by the panel.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Evaluate novel and emerging approaches to prenatal and newborn screening for SMA
  • Describe clinical trial evidence that demonstrates the benefits of early treatment implementation in patients with SMA
  • Analyze appropriate treatments for pediatric and adult patients with SMA based on currently available efficacy and safety data of current and emerging therapies
  • Integrate team-based strategies to improve transition of care in patients with SMA as age increases

Faculty

W. David Arnold, MD

W. David Arnold, MD

Associate Professor - Clinical
Division of Neuromuscular
Department of Neurology
The Ohio State University Wexner Medical Center
Columbus, OH

Nancy L. Kuntz, MD

Nancy L. Kuntz, MD

Attending Physician
Division of Neurology
Mazza Foundation Neuromuscular Program Medical Director
Muscular Dystrophy Association Clinic Ann & Robert H. Lurie Children’s Hospital of Chicago
PPMD Duchenne Care Center and MDA Care Center Professor of Pediatrics and Neurology Northwestern University Feinberg School of Medicine
Chicago, IL

Emma Ciafaloni, MD

Emma Ciafaloni, MD

Robert C. and Rosalyne H. Griggs Professor in Experimental Therapeutics of Neurologic Disease
Professor of Neurology, Pediatrics and Obstetrics and Gynecology
Director Pediatric Neuromuscular Medicine
University of Rochester
Rochester, NY

Debra Guntrum, MS, FNP, ANCC

Debra Guntrum, MS, FNP, ANCC

Nurse Practitioner
Neuromuscular Disease Center
University of Rochester Medical Center
Rochester, NY

Accreditation Statement

Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 1.25  AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.25 Contact Hours.

Disclosures of Conflicts of Interest

In accordance with ACCME guidelines, PER® has identified and resolved all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

W. David Arnold, MD

  • Grant/Research Support: National Institute of Health, NMD Pharma; Consultant: Genentech, Roche.

Nancy L. Kuntz, MD

  • Grant/Research Support: AveXis, Audentes Therapeutics, Biogen, Sarepta Therapeutics
  • Other: MAB: AveXis, argenx, Audentes Therapeutics, Biogen, Roche, Sarepta Therapeutics

Emma Ciafaloni, MD

  • Grant/Research Support: Sarepta Therapeutics, Santhera Pharmaceuticals, FDA, Muscular Dystrophy Association, Cure SMA, Orphazyme, Patient-Centered Outcomes and Research Institute
  • Consultant: Sarepta Therapeutics, Biogen, AveXis, Alexion Pharmaceuticals, argenx, Momenta Pharmaceuticals, Ra Pharmaceuticals
  • Speaker’s Bureau: Biogen

Debra Guntrum, MS, FNP, ANCC

  • No relevant financial relationships with commercial interests to disclose.

The staff of Physicians’ Education Resource®, LLC (PER®), have no relevant financial relationships with commercial interests to disclose.

Instructions for Participation and Credit

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:

  1. Complete the activity (including pre- and postactivity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.
You may immediately download your certificate.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.